COPD
The breath-based biopsy firm is collaborating with Renji Hospital to conduct a clinical trial into the early detection of lung cancer in China.
The drug-device combination measures activity of live organisms by detecting metabolites, and can be used to indicate virulence and guide treatment.Â
The firm is taking its in-home monitoring systems for COPD and cystic fibrosis, and its professional-use sepsis confirmation system through clinical trials.
ProAxsis Proteinase 3 Assay CE Marked
ProAxsis and a US-based biotechnology company codeveloped the assay as part of an ongoing collaboration. ProAxsis has made its first commercial sale of the test.
GSK to use Owlstone's Breath Biopsy for Drug Development Program
GSK will use the Breath Biopsy to assess whether the right treatment for the right patient can be identified, and to evaluate its drug candidate for COPD.